In this article, we will discuss Olaparib (Warnings-2). So, let’s get started. Do not start Olaparib until patients have recovered from hematological toxicity caused by previous chemotherapy (≤ Grade 1). Monitor complete blood count for cytopenia at baseline and monthly thereafter for clinically significant changes during treatment. For prolonged hematological toxicities, interrupt Olaparib and monitor […]
Category: Olaparib
In this article, we will discuss Olaparib (Warnings-1). So, let’s get started. Myelodysplastic Syndrome/Acute Myeloid Leukemia Overall, the incidence of Myelodysplastic Syndrome/Acute Myeloid Leukemia (MDS/AML) in patients treated with Olaparib monotherapy in clinical trials, including long-term follow up, was <1.5% (21/1680) and the majority of events had a fatal outcome. Of these, 19/21 patients had […]
In this article, we will discuss Olaparib (Dosage Strength). So, let’s get started. Dosage Strength Tablets: • 150 mg: green to green/grey, oval, bi-convex, film-coated, with debossment ‘OP150’ on one side and plain on the reverse side. • 100 mg: yellow to dark yellow, oval, bi-convex, film-coated, with debossment ‘OP100’ on one side and plain […]
In this article, we will discuss Olaparib (Dose Modifications-2). So, let’s get started. Dose Modifications for Patients with Renal Impairment Patients with mild renal impairment (CLcr 51-80 mL/min as estimated by Cockcroft-Gault equation) do not require an adjustment in Lynparza dosing. In patients with moderate renal impairment (CLcr 31-50 ml/min) the recommended dose reduction is […]
In this article we will discuss Olaparib (Usage-4)
In this article, we will discuss Olaparib (Dose Modifications-1). So, let’s get started. Dose Modifications for Use with CYP3A Inhibitors Avoid concomitant use of strong or moderate CYP3A inhibitors and consider alternative agents with less CYP3A inhibition. If a strong CYP3A inhibitor must be co-administered, reduce the Olaparib dose to 100 mg (one 100 mg […]